Geneart expands and goes on the stock exchange
In October 2005 Geneart moved from BioPark I to the neighbouring new building BioPark II. With office and laboratory facilities of 1,500 sqm, Geneart is one of the largest tenancy holders at BioPark. The business focus of the company is the production of synthetic genes. Amongst other applications, these are used for the development of innovative medicines and in industrial enzymes. This makes the company one of the first providers certified in accordance with DIN EN ISO 9001:2000. With a global market share of approximately 20 percent, Geneart is one of the leaders worldwide in the area of gene synthesis. The company currently doubles its capacity each year. In the last year the biotech company turned over 4.5 Million Euro und and reached its profit threshold for the first time. Furthermore a subsidiary was founded in Toronto, Canada. Pharmaceutical companies, biotech and chemical companies and research institutions are amongst its customers around the world, approximately 500 in number. Currently the company has over 60 employees, 15 of which have doctorates in the Natural Sciences. To handle its rapid growth more easily and for further financing, the company was transformed from GmbH to AG and now the company is going on the stock exchange. The date for the opening price to the Open Market including Entry Standard to the Frankfurt Stock Exchange was 23 May 2006. The book building took place in the period from 17 - 19 May 2006. Up to 650,000 shares from share capital increase and up to 110,000 shares from financial investors were offered for purchase. Entry to the stock exchange was accompanied by WestLB.
For more information see: